ALNUQBI Trademark

Trademark Overview


On Wednesday, April 19, 2023, a trademark application was filed for ALNUQBI with the United States Patent and Trademark Office. The USPTO has given the ALNUQBI trademark a serial number of 97896310. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, August 20, 2024. This trademark is owned by Bristol-Myers Squibb Company. The ALNUQBI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
alnuqbi

General Information


Serial Number97896310
Word MarkALNUQBI
Filing DateWednesday, April 19, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, August 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 9, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, May 15, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events


Event DateEvent Description
Saturday, April 22, 2023NEW APPLICATION ENTERED
Monday, May 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, August 31, 2023ASSIGNED TO EXAMINER
Thursday, September 7, 2023NON-FINAL ACTION WRITTEN
Thursday, September 7, 2023NON-FINAL ACTION E-MAILED
Thursday, September 7, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 4, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 4, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 4, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 5, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 9, 2024PUBLISHED FOR OPPOSITION
Wednesday, December 20, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 20, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 20, 2024SOU EXTENSION 1 GRANTED
Tuesday, August 20, 2024SOU EXTENSION 1 FILED
Tuesday, March 5, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT